Type 2 Diabetes

An analysis of data from patient surveys provides insight into patient preferences related to oral therapies for type 2 diabetes, with blinded results indicating a preference for SGLT2 inhibitors over oral GLP-1 RA or DPP-4 inhibitors.

People with diabetes in Italy and the UK reported the highest rates of anxiety at 63% and 51%, respectively.

An analysis of data from SURPASS-2 and -3 provides evidence demonstrating the reduction in time to achieve glycemic targets and weight loss with use of tirzepatide compared with semaglutide 1.0 mg and long-acting insulin degludec.

An analysis of data from more than 100,000 hospitalizations for hypoglycemia and hyperglycemic emergencies provides insight into the purported increase in risk for these events observed with extreme heat.

Short-term treatment with rosuvastatin was not linked to changes in insulin resistance markers in a cohort of children with familial hypercholesterolemia.

Released on September 13, the US Preventive Services Task Force concluded there was a lack of sufficient evidence related to the benefits and harms of screening in their first-ever recommendation statement on screening for type 2 diabetes and prediabetes in children with no known history or symptoms of either disease.

Results of the TARGET trial provide insight into the effects of tight glycemic targets versus less tight targets on maternal and perinatal outcomes among women with gestational diabetes.

Black/African American individuals are more likely to have an amputation within the first year following DFU, while women appeared to have a greater likelihood of delayed amputation.

Results of the CREATE trial published in NEJM suggest the use of open-source automated insulin delivery systems was associated with improved time in target glucose range compared with sensor-augmented pump therapy in children and adults with type 1 diabetes.

On September 1, Bayer announced the US FDA had approved a label update for finerenone (Kerendia), which received initial approval in July 2021 for chronic kidney disease associated with type 2 diabetes, to include cardiovascular outcomes data from the FIGARO-DKD trial.

An analysis of patient data from the DCCT and EDIC studies details differences in the cardiometabolic risk factor profiles and management approaches for women and men with type 1 diabetes.

Amy Hess-Fischl, MS, RD, LDN, BC-ADM, CDCES shares clinical pearls for the management of school aged children with diabetes.

An expert in diabetes education provides an overview of dosing requirements and appropriate administration requirements necessary for the administration of hypoglycemia rescue therapies.

A study presented at EASD 22 comparing 600k patients with type 2 diabetes against 1.2 million controls suggests a diagnosis of T2D prior to turning 40 was associated with a more than 5-fold increase in risk of mortality, heart failure hospitalization, and coronary heart disease.

Lower prescriptions for racial, ethnic groups relative to White, non-Hispanic patients remained after accounting for patient- and system-level characteristics.

An analysis of national register data from Sweden suggests elevated HbA1c levels were linked to an increase in the likelihood of developing stenosing tenosynovitis, more commonly known as trigger finger, among people with either type 1 or type 2 diabetes.

In his most recent column, Dr. Gregory Weiss provides perspective on recent data elucidating the links between insulin sensitivity, central adiposity, and atherosclerosis.

An analysis of data from more than 5500 people with type 1 diabetes and preserved kidney function at baseline suggests patients of African Caribbean ethnicity had a more than 50% greater risk of kidney function decline of 50% or greater than patients of other ethnic backgrounds.

Amy Hess-Fischl, MS, RD, LDN, BC-ADM, CDCES reviews the currently available rescue modalities for use in pediatric patients with diabetes experiencing severe hypoglycemia or very low blood sugar.

A certified diabetes educator comments on the some of the available resources for patients, their families, and school staff surrounding the management of diabetes in a school setting.

An analysis assessing the benefits of hybrid closed loop systems in patients with T1D has returned results suggesting improved glycemic control could help preserve neurological function among adolescents with type 1 diabetes.

An expert in diabetes education reviews the signs and symptoms of hypoglycemia and reviews the importance of having school staff members knowledgeable in their presentation.

Amy Hess-Fischl, MS, RD, LDN, BC-ADM, CDCES provide insight into the challenges inherent to the management of pediatric patients with diabetes, highlighting school related considerations.

An analysis of the FIDELITY program from ESC Congress 2022 details an 11% reduction in risk of all-cause mortality and a 25% reduction in risk of sudden cardiac death among patients with type 2 diabetes and chronic kidney disease.

Our endocrinology month in review spotlights the most popular content from the past month. Our top content from August 2022 includes a trial examining time-restricted eating, a pair of FDA decisions, coverage of ADCES 22, and more!